Sunghee Yun (He/Him)

Co-founder & CTO @ Erudio Bio, Inc., Chief Business Development Officer @ WeStory.ai, Advisor & Evangelist @ CryptoLab, Inc., KFAS-Salzburg Global Leadership Initiative Fellow @ Salzburg Global Seminar, Adjunct Professor @ Sogang University, Advisory Professor @ DGIST, Global Advisory Board Member @ Innovative Future Brain-Inspired Intelligence System Semiconductor of Sogang University, Network Expert @ Gerson Lehrman Group

Abstract

In this seminar, we will explore the revolutionary convergence of Artificial Intelligence (AI) and biotechnology that is redefining the landscape of drug discovery. Starting with landmark developments like AlphaFold’s solution to the 50-year-old protein folding problem, we’ll examine how AI technologies—from deep learning to multimodal large language models—are creating unprecedented opportunities to analyze vast amounts of biological data, design novel molecules, and predict therapeutic outcomes with remarkable accuracy and efficiency.

The presentation will delve into emerging trends transforming the biotech industry, including AI-driven personalized medicine, synthetic biology, regenerative medicine, and the integration of disparate biological datasets. We’ll examine how advanced AI platforms are enabling researchers to identify biomarkers, optimize drug candidates, and accelerate the traditionally time-consuming and costly drug development process from years to months, potentially saving billions in development costs while improving success rates.